Abstract
Introduction: New antipsychotics continuously arrive on the market, which thereby influences the approved and off-label prescribing (OLP) schemes. We aimed to identify the recent trends in the OLP of antipsychotics. We conducted a literature review based on three different populations: adult, pediatric, and elderly patients. Methods: A literature search was performed in the PubMed and ScienceDirect databases using the following keyword algorithm: “offlabel” AND (“antipsychotic*” OR “neuroleptic*”). The period investigated ranged from January 2000 to January 2015. Only Englishwritten pharmacoepidemiological studies were included.
Results: Seventy-seven relevant results were identified. Among adults, OLP consisted of 40 to 75% of all antipsychotic prescriptions. The main indications were mood disorders, anxiety disorders, insomnia and agitation. Quetiapine was the most frequently prescribed offlabel antipsychotic, especially for anxiety and insomnia. Among children, OLP was estimated between 36 and 93.2% of all antipsychotic prescriptions. Risperidone and aripiprazole were primarily used and were most often prescribed for attention deficit hyperactivity disorder, anxiety, or mood disorders. Among elderly individuals, OLP consisted of 22 to 86% of all antipsychotic prescriptions. Antipsychotic OLP was particularly frequent for agitation; however, a recent decrease in this OLP was identified.
Discussion: Antipsychotics have largely been prescribed off-label in recent years. The types of antipsychotic OLP practices differ according to the age category of patients. OLP is often used in cases of therapeutic dead-ends or for specific disorders with few or no currently approved medications. However, other OLP practices only reflect temporary prescription trends for mild symptoms, which may induce safety concerns.
Keywords: Adults, antipsychotics, children, elderly, off-label, pharmacoepidemiology, safety.
Current Pharmaceutical Design
Title:Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends
Volume: 21 Issue: 23
Author(s): Louise Carton, Olivier Cottencin, Maryse Lapeyre-Mestre, Pierre A. Geoffroy, Jonathan Favre, Nicolas Simon, Regis Bordet and Benjamin Rolland
Affiliation:
Keywords: Adults, antipsychotics, children, elderly, off-label, pharmacoepidemiology, safety.
Abstract: Introduction: New antipsychotics continuously arrive on the market, which thereby influences the approved and off-label prescribing (OLP) schemes. We aimed to identify the recent trends in the OLP of antipsychotics. We conducted a literature review based on three different populations: adult, pediatric, and elderly patients. Methods: A literature search was performed in the PubMed and ScienceDirect databases using the following keyword algorithm: “offlabel” AND (“antipsychotic*” OR “neuroleptic*”). The period investigated ranged from January 2000 to January 2015. Only Englishwritten pharmacoepidemiological studies were included.
Results: Seventy-seven relevant results were identified. Among adults, OLP consisted of 40 to 75% of all antipsychotic prescriptions. The main indications were mood disorders, anxiety disorders, insomnia and agitation. Quetiapine was the most frequently prescribed offlabel antipsychotic, especially for anxiety and insomnia. Among children, OLP was estimated between 36 and 93.2% of all antipsychotic prescriptions. Risperidone and aripiprazole were primarily used and were most often prescribed for attention deficit hyperactivity disorder, anxiety, or mood disorders. Among elderly individuals, OLP consisted of 22 to 86% of all antipsychotic prescriptions. Antipsychotic OLP was particularly frequent for agitation; however, a recent decrease in this OLP was identified.
Discussion: Antipsychotics have largely been prescribed off-label in recent years. The types of antipsychotic OLP practices differ according to the age category of patients. OLP is often used in cases of therapeutic dead-ends or for specific disorders with few or no currently approved medications. However, other OLP practices only reflect temporary prescription trends for mild symptoms, which may induce safety concerns.
Export Options
About this article
Cite this article as:
Carton Louise, Cottencin Olivier, Lapeyre-Mestre Maryse, Geoffroy A. Pierre, Favre Jonathan, Simon Nicolas, Bordet Regis and Rolland Benjamin, Off-Label Prescribing of Antipsychotics in Adults, Children and Elderly Individuals: A Systematic Review of Recent Prescription Trends, Current Pharmaceutical Design 2015; 21 (23) . https://dx.doi.org/10.2174/1381612821666150619092903
DOI https://dx.doi.org/10.2174/1381612821666150619092903 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Clinical Use of Neurophysiological Biomarkers and Self-Assessment Scales to Predict and Monitor Treatment Response for Psychotic and Affective Disorders
Current Pharmaceutical Design Synthesis, Characterization and Potential Applications of Multifunctional PEO-PPOPEO- Magnetic Drug Delivery System
Current Medicinal Chemistry Dancing as an Intervention Tool for People with Dementia: A Mini-Review Dancing and Dementia
Current Alzheimer Research Diabetes Mellitus to Neurodegenerative Disorders: Is Oxidative Stress Fueling the Flame?
CNS & Neurological Disorders - Drug Targets Butyrylcholinesterase as a Diagnostic and Therapeutic Target for Alzheimer’s Disease
Current Alzheimer Research Creutzfeldt-Jakob, Parkinson, Lewy Body Dementia and Alzheimer Diseases: From Diagnosis to Therapy
Central Nervous System Agents in Medicinal Chemistry Current Issues in the Use of fMRI-Based Neurofeedback to Relieve Psychiatric Symptoms
Current Pharmaceutical Design Choline Nutrition Programs Brain Development Via DNA and Histone Methylation
Central Nervous System Agents in Medicinal Chemistry Ethanol and Inflammation
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Comparison of Mono-dopaminergic and Multi-target Pharmacotherapies in Primary Parkinson Syndrome and Assessment Tools to Evaluate Motor and Non-motor Symptoms
Current Drug Therapy Monoamine Oxidase Inhibitors Extracted from Tobacco Smoke as Neuroprotective Factors for Potential Treatment of Parkinson`s Disease
CNS & Neurological Disorders - Drug Targets Congenital Blood Coagulation Factor XIII Deficiency and Perinatal Management
Current Drug Targets Fibrinolytic Enzymes From Extremophilic Microorganisms in the Development of New Thrombolytic Therapies: Technological Prospecting
Recent Patents on Biotechnology The Role of IRE1 Signaling in the Central Nervous System Diseases
Current Neuropharmacology Chemistry and Biology of Thyrotropin-Releasing Hormone (TRH) and its Analogs
Current Medicinal Chemistry Regulatory Role of Chinese Herbal Medicine in Regulated Neuronal Death
CNS & Neurological Disorders - Drug Targets Mitochondria: Prospective Targets for Neuroprotection in Parkinson's Disease
Current Pharmaceutical Design A Feature-Free 30-Disease Pathological Brain Detection System by Linear Regression Classifier
CNS & Neurological Disorders - Drug Targets Autism Spectrum Disorders: Etiology and Pharmacotherapy
Current Drug Therapy Meet Our Editorial Board Member:
Current Alzheimer Research